A citation-based method for searching scientific literature

Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein, Claire Bournaud-Salinas, Jean-Louis Wemeau, Anne Gimbert, Marie-Quitterie Picat, Delphine Pedenon, Laurence Digue, Amaury Daste, Bogdan Catargi, Jean-Pierre Delord. Eur J Cancer 2017
Times Cited: 63







List of co-cited articles
959 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
843
63

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
858
61

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
956
55

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
664
49

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
284
47

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
239
41

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
363
41

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
135
39


Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott,[...]. J Clin Oncol 2008
463
36

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Kostandinos Sideras, John C Morris, Bryan McIver,[...]. Lancet Oncol 2010
306
36

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Keith C Bible, Vera J Suman, Michael E Menefee, Robert C Smallridge, Julian R Molina, William J Maples, Nina J Karlin, Anne M Traynor, Priya Kumar, Boon Cher Goh,[...]. J Clin Endocrinol Metab 2012
109
33

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
552
33

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
177
31

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris,[...]. J Clin Endocrinol Metab 2014
72
31

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
72
31

Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Athanasios Bikas, Priya Kundra, Sameer Desale, Mihriye Mete, Kaitlyn O'Keefe, Brandon G Clark, Lynette Wray, Rahul Gandhi, Christina Barett, James S Jelinek,[...]. Eur J Endocrinol 2016
39
48

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
468
30

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits,[...]. Clin Cancer Res 2018
45
42

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
28

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
274
28

An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Sun Min Lim, Woong Youn Chung, Kee-Hyun Nam, Sang-Wook Kang, Jae Yun Lim, Hoon-Gu Kim, Seong Hoon Shin, Jong-Mu Sun, Seong-Geun Kim, Joo-Hang Kim,[...]. Eur J Cancer 2015
34
52

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
943
26

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
S M Lim, H Chang, M J Yoon, Y K Hong, H Kim, W Y Chung, C S Park, K H Nam, S W Kang, M K Kim,[...]. Ann Oncol 2013
90
26

Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
499
25

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada. Thyroid 2017
46
34

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
349
23

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Panayiotis Savvides, Govardhanan Nagaiah, Pierre Lavertu, Pingfu Fu, John J Wright, Robert Chapman, Jay Wasman, Afshin Dowlati, Scot C Remick. Thyroid 2013
129
23

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
85
22

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J Sherman, Lara A Dunn, Alan L Ho, Shrujal S Baxi, Ronald A Ghossein, Matthew G Fury, Sofia Haque, Cami S Sima, Grace Cullen, James A Fagin,[...]. Cancer 2017
42
33

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
181
22

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.
Robert C Smallridge, Kenneth B Ain, Sylvia L Asa, Keith C Bible, James D Brierley, Kenneth D Burman, Electron Kebebew, Nancy Y Lee, Yuri E Nikiforov, M Sara Rosenthal,[...]. Thyroid 2012
437
20

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
922
20

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Maria E Cabanillas, Martin Schlumberger, Barbara Jarzab, Renato G Martins, Furio Pacini, Bruce Robinson, Judith C McCaffrey, Manisha H Shah, Donald L Bodenner, Duncan Topliss,[...]. Cancer 2015
121
20

Phase II trial of sorafenib in metastatic thyroid cancer.
Richard T Kloos, Matthew D Ringel, Michael V Knopp, Nathan C Hall, Mark King, Robert Stevens, Jiachao Liang, Paul E Wakely, Vasyl V Vasko, Motoyasu Saji,[...]. J Clin Oncol 2009
402
20

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
20

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Priyanka C Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D Williams, G Brandon Gunn, Horiana Grosu,[...]. J Immunother Cancer 2018
93
20

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Janice M Mehnert, Andrea Varga, Marcia S Brose, Rahul R Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A Piha-Paul,[...]. BMC Cancer 2019
74
20

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Tatiana C Schneider, Djoeke de Wit, Thera P Links, Nielka P van Erp, Jakobus J M van der Hoeven, Hans Gelderblom, Inge C F M Roozen, Manon Bos, Wim E Corver, Tom van Wezel,[...]. J Clin Endocrinol Metab 2017
47
25

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
123
19



Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
205
19

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Laura D Locati, Lisa Licitra, Laura Agate, Sai-Hong I Ou, Andree Boucher, Barbara Jarzab, Shukui Qin, Madeleine A Kane, Lori J Wirth, Connie Chen,[...]. Cancer 2014
73
17

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz,[...]. J Clin Oncol 2009
257
17

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
55
20

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
168
17

Lenvatinib for Anaplastic Thyroid Cancer.
Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Front Oncol 2017
88
17

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Jaume Capdevila, José Manuel Trigo, Javier Aller, José Luís Manzano, Silvia García Adrián, Carles Zafón Llopis, Òscar Reig, Uriel Bohn, Teresa Ramón Y Cajal, Manuel Duran-Poveda,[...]. Eur J Endocrinol 2017
19
57

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
201
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.